Back to top

medical-devices: Archive

Zacks Equity Research

Tandem Diabetes (TNDM) Posts Narrower Q1 Loss, Raises '24 View

Tandem Diabetes (TNDM) outperforms in the first quarter, backed by the demand for both t:slim X2 and the newly launched Tandem Mobi.

TNDMPositive Net Change MEDPNegative Net Change EHCPositive Net Change TMDXPositive Net Change

Zacks Equity Research

DENTSPLY SIRONA (XRAY) Q1 Earnings In Line, Revenues Decline Y/Y

DENTSPLY SIRONA's (XRAY) first-quarter 2024 results showcase a decline in year-over-year sales with an improved bottom line.

BSXNegative Net Change ECLNegative Net Change ALGNNegative Net Change XRAYNegative Net Change

Zacks Equity Research

Envista (NVST) Q1 Earnings Miss Estimates, Margins Down

Envista (NVST) registers a year-over-year decline in both segments in the first quarter of 2024.

BSXNegative Net Change ALGNNegative Net Change RMDNegative Net Change NVSTNegative Net Change

Zacks Equity Research

Reasons to Retain Quest Diagnostics (DGX) Stock for Now

Investors are optimistic about Quest Diagnostics (DGX) on strong legacy business growth.

BSXNegative Net Change DGXPositive Net Change ALGNNegative Net Change RMDNegative Net Change

Zacks Equity Research

Cardinal Health (CAH) Beats on Q3 Earnings, Ups '24 EPS View

Cardinal Health's (CAH) third-quarter fiscal 2024 results benefit from solid profit growth in Pharmaceutical and Specialty Solutions. The company raises its EPS guidance for fiscal 2024.

BSXNegative Net Change ECLNegative Net Change ALGNNegative Net Change CAHPositive Net Change

Zacks Equity Research

Baxter (BAX) Q1 Earnings Beat Estimates, '24 EPS View Raised

Baxter (BAX) reports better-than-expected first-quarter earnings and sales. BAX's quarterly results reflect solid demand for a range of its medically essential products.

BSXNegative Net Change ECLNegative Net Change BAXNegative Net Change ALGNNegative Net Change

Zacks Equity Research

BD (BDX) Q2 Earnings Surpass Estimates, FY24 View Revised

BD's (BDX) overall top line benefits from revenue growth in all segments and both geographic regions in the fiscal second quarter.

BSXNegative Net Change BDXPositive Net Change ALGNNegative Net Change RMDNegative Net Change

Zacks Equity Research

Accuray (ARAY) Q3 Earnings Lag Estimates, Gross Margin Contracts

Despite strength in radiation oncology, Accuray (ARAY) reports dismal third-quarter fiscal 2024 results.

BSXNegative Net Change ARAYNegative Net Change ALGNNegative Net Change RMDNegative Net Change

Zacks Equity Research

Glaukos (GKOS) Q1 Earnings Miss Estimates, Revenues Up Y/Y

Glaukos' (GKOS) first-quarter 2024 results showcase growth in revenues while earnings miss the Zacks consensus Estimate. Loss at the operating level raises concern as well.

BSXNegative Net Change ECLNegative Net Change ALGNNegative Net Change GKOSPositive Net Change

Zacks Equity Research

Quest Diagnostics (DGX) Inks Deal to Acquire PathAI Diagnostics

Quest Diagnostics' (DGX) latest transaction combines its oncology expertise and scale with PathAI's AI and digital pathology innovations.

DGXPositive Net Change RMDNegative Net Change HCAPositive Net Change MEDPNegative Net Change

Zacks Equity Research

Here's Why You Should Retain STERIS (STE) Stock for Now

STERIS' (STE) strong prospects in the healthcare and pharmaceutical industries bode well for investors.

BSXNegative Net Change HCAPositive Net Change STEPositive Net Change INSPNegative Net Change

Mark Vickery

Top Research Reports for Thermo Fisher Scientific, Walt Disney & Southern Copper

Today's Research Daily features new research reports on 16 major stocks, including Thermo Fisher Scientific Inc. (TMO), The Walt Disney Company (DIS) and Southern Copper Corporation (SCCO).

PEGPositive Net Change OMCPositive Net Change TMOPositive Net Change TSCOPositive Net Change DISNegative Net Change SCCOPositive Net Change

Zacks Equity Research

Strength in Kidney Care Likely to Aid DaVita's (DVA) Q1 Earnings

Improvement in revenue per treatment and cost-saving initiatives are likely to have boosted DaVita's (DVA) top line in the first quarter.

DVANegative Net Change BPMCNegative Net Change GRTSNegative Net Change ERASNegative Net Change

Zacks Equity Research

Merit Medical (MMSI) Q1 Earnings Top Estimates, Margins Up

Merit Medical (MMSI) benefits from revenue growth in both segments and the majority of its product categories within its Cardiovascular unit in the first quarter.

BSXNegative Net Change ALGNNegative Net Change RMDNegative Net Change MMSIPositive Net Change

Zacks Equity Research

What's in Store for These 5 Medical Device Stocks in Q1 Earnings?

Here is a sneak peek into how five medical device stocks, BDX, BAX, XRAY, CAH and DVA, might fare in their quarterly results slated to be released tomorrow.

BDXPositive Net Change BAXNegative Net Change DVANegative Net Change CAHPositive Net Change XRAYNegative Net Change

Zacks Equity Research

CVS Health's (CVS) Q1 Earnings Miss Estimates, Margins Up

CVS Health's (CVS) Q1 performance is impacted by a decline in the Health Services segment due to continued pharmacy client price improvements.

BSXNegative Net Change ALGNNegative Net Change RMDNegative Net Change CVSPositive Net Change

Zacks Equity Research

Organon (OGN) Gears Up to Report Q1 Earnings: What's in Store?

Organon's (OGN) first-quarter results are likely to reflect growth in its biosimilars and established brand franchises with lighter fertility product sales amid foreign exchange headwinds.

BPMCNegative Net Change NVCRPositive Net Change SIBNNegative Net Change OGNNegative Net Change

Zacks Equity Research

Inari Medical (NARI) Q1 Earnings Miss Estimates, OpEx Rises

Inari Medical's (NARI) first-quarter results witness an increase in revenues with dismal bottom-line performance. Gross margins contract while the companies continue to incur operating losses.

BSXNegative Net Change ECLNegative Net Change ALGNNegative Net Change NARIPositive Net Change

Zacks Equity Research

IDEXX (IDXX) Q1 Earnings Surpass Estimates, 2024 View Slashed

IDEXX (IDXX) delivers better-than-expected earnings in the first quarter of 2024.

BSXNegative Net Change IDXXPositive Net Change MEDPNegative Net Change EHCPositive Net Change

Zacks Equity Research

Stryker's (SYK) Q1 Earnings Beat Estimates, Guidance Raised

Stryker's (SYK) first-quarter earnings reflect strong performance across its segments and geographies. Operating and gross margins increase, with earnings and revenues beating their respective estimates.

BSXNegative Net Change SYKNegative Net Change ALGNNegative Net Change MEDPNegative Net Change

Indrajit Bandyopadhyay

What's in Store for These 4 Medical Device Stocks in Q1 Earnings?

Here is a sneak peek into how the four medical device stocks, COR, GKOS, ARAY and SRDX, might fare in their quarterly results slated to be release tomorrow.

ARAYNegative Net Change SRDXNegative Net Change CORPositive Net Change GKOSPositive Net Change

Zacks Equity Research

Cencora (COR) Q2 Earnings Top Estimates, 2024 View Raised

Cencora's (COR) second-quarter fiscal 2024 results benefit from overall market growth, including rising demand for GLP-1 drugs and COVID-19 vaccines. Inflationary pressure remains.

BSXNegative Net Change ALGNNegative Net Change CORPositive Net Change MEDPNegative Net Change

Zacks Equity Research

Stock Market News for May 1, 2024

U.S. stock markets tumbled Tuesday, closing sharply lower.

GEHCPositive Net Change

Zacks Equity Research

Here's Why You Should Hold Lantheus (LNTH) in Your Portfolio Now

Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.

ECLNegative Net Change BDXPositive Net Change ALGNNegative Net Change LNTHPositive Net Change

Zacks Equity Research

GE HealthCare (GEHC) Q1 Earnings In Line, Sales Volume Decline

GE HealthCare's (GEHC) first-quarter results witness declining segmental revenues in imaging, ultrasound and patient care. The bottom line improves on better pricing.

ECLNegative Net Change BDXPositive Net Change ALGNNegative Net Change GEHCPositive Net Change